Evidence-based medicine is the new paradigm of modern clinical practice and research, and the new direction of international clinical medicine development. Its core idea is to perfectly combine the best clinical research evidence, the clinician’s personal expertise, and the actual condition and wishes of the patient in medical decision making, so as to achieve the best clinical results. The failure of traditional antiepileptic drugs to provide the best outcomes for patients with epilepsy has led to the gradual development of newer antiepileptic drugs. Currently, the new antiepileptic drugs include gabapentin, lamotrigine, topiramate, oxcarbazepine, tiagabine, levetiracetam, and zonisamide, bringing new opportunities and challenges to epilepsy treatment. For physicians involved in epilepsy diagnosis and treatment, it is important to seek medications that are well tolerated, have few side effects, and have minimal impact on life. As there are more types of epilepsy, what is the efficacy of each type of epilepsy on newer antiepileptic drugs, what are the common and serious adverse effects of various newer antiepileptic drugs in clinical application, and what to pay attention to in terms of dosing and dosing methods are the current issues before clinicians. The American Academy of Neurology and the American Epilepsy Society, evaluate the above FDA-approved seven new antiepileptic drugs and propose evidence-based medical guidelines.